Plasmapheresis in myasthenia gravis. A comparative study of daily versus alternately daily schedule.

The aim of this study was to compare the efficacy of different protocols of plasmapheresis in the treatment of myasthenia gravis (MG).
We treated 30 MG patients with plasmapheresis on either a daily or alternately daily schedule for 5 consecutive sessions. Acetylcholine receptor antibody (AchRAb), serum proteins including albumin, globulin, immunoglobulin G (IgG), IgA, and IgM, and MG score were measured before and after the course of plasmapheresis in each group of patients.
The mean percent reductions of serum proteins including IgA (81.5% vs 69.7%), IgM (95.6% vs 87.1%), and globulin (63.2% vs 50.1%) were significantly higher in the daily group. There were no significant differences in AchRAb and IgG levels after treatment between these 2 groups. However, the reduction of MG score was greater in the daily group. All the patients tolerated plasmapheresis well except for 2.7% of them who experienced hypotension.
Our results suggest that daily plasmapheresis may be more effective in the treatment of patients with advanced MG.
AuthorsJ H Yeh, H C Chiu
JournalActa neurologica Scandinavica (Acta Neurol Scand) Vol. 99 Issue 3 Pg. 147-51 (Mar 1999) ISSN: 0001-6314 [Print] DENMARK
PMID10100957 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
  • Adult
  • Aged
  • Appointments and Schedules
  • Chi-Square Distribution
  • Clinical Protocols (standards)
  • Female
  • Filtration (methods)
  • Humans
  • Male
  • Middle Aged
  • Myasthenia Gravis (therapy)
  • Plasmapheresis (methods)
  • Prospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: